Arrowstreet Capital Limited Partnership Has $166.81 Million Stock Holdings in Charles River Laboratories International, Inc. $CRL

Arrowstreet Capital Limited Partnership raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.7% during the 4th quarter, HoldingsChannel reports. The fund owned 836,240 shares of the medical research company’s stock after buying an additional 66,803 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Charles River Laboratories International were worth $166,813,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Cardinal Capital Management increased its stake in Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after buying an additional 62 shares during the last quarter. Asset Management One Co. Ltd. grew its holdings in shares of Charles River Laboratories International by 4.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 71 shares in the last quarter. Advisory Services Network LLC increased its position in shares of Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC increased its position in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the last quarter. Finally, Exencial Wealth Advisors LLC raised its holdings in Charles River Laboratories International by 3.1% during the fourth quarter. Exencial Wealth Advisors LLC now owns 2,886 shares of the medical research company’s stock worth $576,000 after acquiring an additional 87 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on CRL. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target for the company. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price objective for the company from $167.00 to $219.00 in a report on Friday, May 29th. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $208.50.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $188.74 on Tuesday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock’s 50 day moving average price is $173.80 and its two-hundred day moving average price is $182.57. The firm has a market capitalization of $9.09 billion, a price-to-earnings ratio of -50.20, a P/E/G ratio of 2.14 and a beta of 1.46. Charles River Laboratories International, Inc. has a 12-month low of $143.06 and a 12-month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.